|
Jul 8
|
Trump Says He’ll Set 50% Copper Tariff, Wait Year on Drug Levies
|
|
Jul 8
|
Merck (NYSE:MRK) To Present Promising HIV Research Data At IAS 2025 In Kigali
|
|
Jul 8
|
AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?
|
|
Jul 8
|
Equine Healthcare Market Research and Forecast Report 2025-2034 | Top Players Drive Innovations, Strategic Collaborations and Product Expansion on the Rise
|
|
Jul 8
|
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
|
|
Jul 8
|
Impactivize: Shareholders of 30 Companies Worth $13 Trillion Vote Overwhelmingly to Defeat Anti-DEI Proposals
|
|
Jul 8
|
Certara Announces Expansion of Clinical Technology Collaboration with Merck
|
|
Jul 8
|
Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025
|
|
Jul 8
|
Analysis: 'Trump Effect' website takes credit for US investment made under Biden
|
|
Jul 7
|
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
|
|
Jul 7
|
Exelixis Surges 35.2% in Three Months: Buy or Sell the Stock?
|
|
Jul 7
|
SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca
|
|
Jul 7
|
mRNA Cancer Vaccines Clinical Trials & Future Market Outlook 2025: Personalized mRNA Cancer Vaccines Revolutionize Oncology with Neoantigen-Driven Immunotherapy
|
|
Jul 6
|
FDA Grants Priority Review for Merck & Co’s (MRK) WINREVAIR
|
|
Jul 6
|
Merck & Co (MRK) Announces the Approval of ENFLONSIA
|
|
Jul 4
|
Top Dividend Stocks To Consider In July 2025
|
|
Jul 4
|
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
|
|
Jul 4
|
Sodium Perborate Market worth $184.0 million in 2030, at 3.7%, says MarketsandMarkets™
|
|
Jul 4
|
TD Cowen Maintains Hold Rating on Merck After Enflonsia Vaccine Update
|
|
Jul 2
|
Merck's Drug Slashes PAH Risk by 76%--FDA Fast-Tracks Game-Changer
|